New shot could stop dangerous swelling attacks in HAE

NCT ID NCT06842823

Ongoing Disease control Sponsor: Astria Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if the drug reduces the number of confirmed HAE attacks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: navenibart (also called STAR-0215), given as a shot under the skin
What this could lead to: If it works, this could give people with HAE a new option to prevent painful and dangerous swelling attacks.
What could go wrong: This is still a controlled trial, so we don't know yet if navenibart works better than placebo. It may not prevent attacks for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioedema hereditary angioedema type 1 hereditary angioedema type 2 hereditary angioedema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA (HAE)

Contacts and locations

Locations

Site 1

Walnut Creek, California, 94598, United States
Site 10

St Louis, Missouri, 63141, United States
Site 11

Colorado Springs, Colorado, 80907, United States
Site 12

Toledo, Ohio, 43617, United States
Site 13

Detroit, Michigan, 48202, United States
Site 14

San Diego, California, 92123,, United States
Site 15

Hummelstown, Pennsylvania, 17036, United States
Site 16

Cambridge, CB2 0QQ, United Kingdom
Site 17

London, E1 2ES, United Kingdom
Site 18

Plymouth, Devon, PL6 8HD, United Kingdom
Site 19

Bristol, BS10 5N, United Kingdom
Site 2

Scottsdale, Arizona, 85251, United States
Site 20

Hong Kong, Hong Kong
Site 21

Cape Town, 7700, South Africa
Site 22

Frimley, GU16 7UJ, United Kingdom
Site 23

Edmonton, AB T6G 2B7, Canada
Site 24

Hampstead, London, NW3 2QG, United Kingdom
Site 25

Tampa, Florida, 33613, United States
Site 26

San Diego, California, 92122, United States
Site 27

Amsterdam, Netherlands
Site 28

Sofia, 1680, Bulgaria
Site 29

Rzeszów, 35-051, Poland
Site 3

Little Rock, Arkansas, 72205, United States
Site 30

Fukuoka, Kurume-shi, 830-0011, Japan
Site 31

Saitama, Soka-shi, 340-0041, Japan
Site 32

Barcelona, Spain
Site 33

Skopje, 1000, North Macedonia
Site 34

Petah Tikva, 4920235, Israel
Site 35

Petah Tikva, 49100, Israel
Site 36

Valencia, 46026, Spain
Site 37

Hradec Králové, 500 05, Czechia
Site 38

Berlin, 12203, Germany
Site 39

Prague, 150 06, Czechia
Site 4

Santa Monica, California, 90404, United States
Site 40

San Donato Milanese, 20097, Italy
Site 41

Torino, 10128, Italy
Site 42

Milan, 20138, Italy
Site 44

Frankfurt, D-60590, Germany
Site 45

Santo André, 09060870, Brazil
Site 46

La Tronche, 38700, France
Site 47

Saga, 849-8501, Japan
Site 48

Seville, 41013, Spain
Site 49

Haifa, 3104802, Israel
Site 5

Ottawa, Ontario, K1H 1E4, Canada
Site 50

Hiroshima, 734-8551, Japan
Site 51

Monserrato, 09042, Italy
Site 51

Monserrato, CA 09042, Italy
Site 52

Paris, 75012, France
Site 53

Tel Aviv, 6423906, Israel
Site 54

Lille, 59037, France
Site 55

Ashkelon, 7830604, Israel
Site 56

Tsu, Mei, 514-8507, Japan
Site 57

Hiroshima, 730-8518, Japan
Site 58

Kawasaki, 216-8511, Japan
Site 59

San Juan, 00918, Puerto Rico
Site 6

Wheaton, Maryland, 20902, United States
Site 60

Yangcheon, Seoul, South Korea
Site 61

Kawagoe, Saitama, 350-8550, Japan
Site 62

Seoul, Jongno, South Korea
Site 63

Madrid, 28007, Spain
Site 64

Budapest, 1088, Hungary
Site 65

Marseille, 13005, France
Site 66

Padova, 35128, Italy
Site 67

Boston, Massachusetts, 02114, United States
Site 68

Campbelltown, New South Wales, 2560, Australia
Site 69

Weston, Florida, 33331, United States
Site 7

Cincinnati, Ohio, 45236, United States
Site 70

Hanover, 30625, Germany
Site 71

Krakow, 31-503, Poland
Site 72

Nice, 06202, France
Site 73

Tokyo, 173-0032, Japan
Site 74

Murdoch, WA 6150, Australia
Site 75

Auckland, New Zealand
Site 76

Melbourne, Victoria, Australia
Site 77

Seongnam-si, South Korea
Site 78

Lodz, 92-213, Poland
Site 79

Warsaw, 04-141, Poland
Site 8

Centennial, Colorado, 80112, United States
Site 80

Nagasaki, 852-8501, Japan
Site 81

Coimbra, 3004-561, Portugal
Site 82

Lisbon, 1649-028, Portugal
Site 83

Vienna, 1090, Austria
Site 84

Santa Cruz de Tenerife, 38010, Spain
Site 85

Milan, 20157, Italy
Site 86

Dallas, Texas, 75231, United States
Site 9

Birmingham, Alabama, 35209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.